Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach
Atrial Fibrillation Market
Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) — The “Atrial Fibrillation Market by Treatment, Type of Drug, Type of Drug Molecule, Type of Target, Route of Administration, Type of Device, Type of Technology, End User, Geographical Regions and Sales Forecast – Trends and Forecast Till 2035” has been added to ResearchAndMarkets.com’s offering.
The global atrial fibrillation market is projected to increase from USD 21.4 billion in 2026 to USD 38.7 billion by 2035, representing a compound annual growth rate of 6.8% during the forecast period. Market expansion is being supported by the rising prevalence of atrial fibrillation, growth of the geriatric population, increasing cardiovascular risk factors, and rapid adoption of advanced diagnostic and treatment technologies.
Atrial Fibrillation Market Growth and Trends
Atrial fibrillation represents a substantial clinical and economic burden because of its association with stroke, heart failure, and other cardiovascular complications. Prevalence rises considerably with age and is elevated among patients with hypertension, diabetes, obesity, and related comorbidities. According to the Centers for Disease Control and Prevention, atrial fibrillation remained the most commonly treated cardiac arrhythmia in the United States in 2024. The affected US population is projected to reach approximately 12.1 million by 2030.
The atrial fibrillation treatment landscape is evolving beyond conventional rate and rhythm control medications and warfarin-based stroke prevention. Direct oral anticoagulants, next-generation catheter ablation systems, left atrial appendage closure devices, wearable technologies, and remote patient monitoring platforms are supporting earlier detection and more personalized treatment. The growing emphasis on rhythm control and proactive stroke prevention is expected to create sustained opportunities for drug developers, medical device manufacturers, digital health companies, and healthcare providers.
Artificial intelligence-enabled diagnostics, continuous monitoring technologies, and broader screening programs are improving the identification of asymptomatic and paroxysmal atrial fibrillation. However, underdiagnosis remains a significant market barrier. Other challenges include the high cost of advanced interventions, regional differences in reimbursement, anticoagulant-related bleeding risks, treatment adherence, and the complexity of managing patients with multiple cardiovascular and metabolic conditions. Data accuracy, interoperability, regulatory compliance, and clinical validation also remain important considerations for digital health solutions.
Key Atrial Fibrillation Market Insights
- Approximately 55% of atrial fibrillation therapy developers are based in North America.
- Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach.
- Nearly 60 catheter ablation and left atrial appendage closure devices are marketed or under development.
- Catheters represent approximately 40% of current atrial fibrillation treatment devices.
- About 51% of the evaluated clinical trials are recruiting participants.
- Approximately 45% of discontinued atrial fibrillation drugs were terminated during Phase II clinical trials.
- Close to 30% of relevant patents were published in 2025, with industry participants filing approximately 70% of those patents.
- Stakeholders have raised nearly USD 1.28 billion across multiple funding rounds, with venture capital representing the leading financing model.
- Acquisitions account for approximately 40% of identified transactions as larger companies expand their ablation, left atrial appendage closure, and anticoagulant portfolios.
- The atrial fibrillation treatment devices market is projected to grow at a CAGR of 13.1%, supported by advanced ablation systems, investments, and strategic partnerships.
Market Segmentation and Regional Outlook
The atrial fibrillation market analysis covers drugs and devices. Drug segments include antiarrhythmics and anticoagulants, biologics and small molecules, and therapies targeting Factor Xa, Factor XI, ion channels, and vitamin K pathways. Routes of administration include oral and subcutaneous delivery. Device segments include catheter ablation and left atrial appendage closure systems, with technologies spanning cryoablation, pulse field ablation, radiofrequency ablation, and other energy sources.
Small molecule therapies currently hold the largest market share and are expected to retain their leadership through 2035. Their position is supported by established clinical use, oral administration, scalable manufacturing, and widespread adoption of anticoagulant and antiarrhythmic medicines.
North America is projected to remain the largest regional atrial fibrillation market through 2035. Its leadership is supported by high disease prevalence, established healthcare infrastructure, favorable reimbursement frameworks, and early adoption of pulse field ablation and left atrial appendage closure devices. The Asia-Pacific market is expected to record the fastest growth, driven by population aging, increasing cardiovascular disease prevalence, improving healthcare infrastructure, and expanding access to advanced diagnosis and treatment.
Hospitals currently account for more than 80% of the end-user market. Their dominance reflects the availability of electrophysiology laboratories, specialized cardiac care teams, advanced diagnostic capabilities, and the infrastructure required for complex catheter ablation procedures. Additional end users include cardiac catheterization laboratories and ambulatory surgical centers.
Leading Companies in the Atrial Fibrillation Market
- Abbott
- AtriCure
- Boston Scientific
- Bristol Myers Squibb
- Cadrenal Therapeutics
- Daiichi Sankyo
- Johnson & Johnson
- Medtronic
- Novartis
- Sanofi
Research Coverage
The market report provides revenue forecasts and opportunity analysis by treatment, drug type, molecule type, therapeutic target, route of administration, device category, technology, end user, and geography. Regional coverage includes North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America, with country-level analysis of major healthcare markets.
The study also evaluates atrial fibrillation therapy pipelines, treatment device portfolios, clinical trials, discontinued drug programs, recently approved therapies, patents, partnerships, acquisitions, funding activity, and industry events. Company profiles assess product portfolios, management teams, geographic presence, and strategic initiatives. Competitive analysis addresses barriers to entry, buyer and provider influence, substitute technologies, and rivalry among established market participants.
Primary research incorporates perspectives from cardiologists, senior cardiac rhythm management executives, chief medical officers, cardiac surgery leaders, clinical research specialists, and executives at emerging atrial fibrillation companies in the United States, New Zealand, and Switzerland.
Strategic Value of the Report
The report is designed to help established companies, emerging entrants, investors, and healthcare stakeholders evaluate the current atrial fibrillation market size, forecast growth, identify high-potential segments, and understand competitive dynamics. It provides insight into market drivers, access barriers, customer demand, technology adoption, clinical development, and regional opportunities.
Additional benefits include Excel data packs for analytical modules, up to 15% complimentary content customization, an in-depth report walkthrough with the research team, and a complimentary update when the purchased report is more than six months old.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 210 |
| Forecast Period | 2026-2035 |
| Estimated Market Value (USD) in 2026 | $21.4 Billion |
| Forecasted Market Value (USD) by 2035 | $38.7 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/aavnne
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Atrial Fibrillation Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
